Product Highlight - Xarelto

The First & Only NOAC Approved for CAD/PAD^1*
Xarelto, co-administered with ASA, is indicated for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.²

In the COMPASS trial, Xarelto 2.5 mg bid + aspirin vs aspirin alone:
• -24% primary outcome: CV death, stroke or MI (p<0.001)³
• -23% all-cause mortality in CAD patients (p=0.0012)⁴
• -46% MALE and major amputations in PAD patients (p=0.0037)⁵
• No significant increase in the risk of most serious bleeding³
• Recommended by the 2019 ESC⁶ and ESVM⁷ Guidelines

ASA: acetylsalicylic acid; CAD: coronary artery disease; CV: cardiovascular; ESC: European Society of Cardiology; ESVM: European Society for Vascular Medicine; MALE: major adverse limb events; MI: myocardial infarction; NOAC: non-vitamin K oral anticoagulant; PAD: peripheral artery disease.

*As of Apr 1, 2020

References:
1. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) [news release]. Titusville, NJ; October 11, 2018: Janssen Pharmaceuticals website. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Accessed Apr 1, 2020.
2. Xarelto Hong Kong prescribing information.
3. Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330.
4. Connolly SJ, et al. Lancet 2017; doi: 10.1016/S0140–6736(17)32458–3.
5. Anand SS, et al. J Am Coll Cardiol 2019;73:3271–80.
6. Neumann FJ, et al. European Heart Journal (2019) 00, 1-71. doi:10.1093/eurheartj/ehz425.
7. Frank U, et al. Vasa (2019), 48 (Supplement 102).